Trends in Costs for HIV Care During a Hepatitis C Virus Early Treatment and Elimination Program: A Data Linkage Study of Claims and Swiss HIV Cohort Study Data - Takeaways - MDSpire

Trends in Costs for HIV Care During a Hepatitis C Virus Early Treatment and Elimination Program: A Data Linkage Study of Claims and Swiss HIV Cohort Study Data

  • By

  • Soheila Aghlmandi

  • Kurt Schmidlin

  • Carola Huber

  • Pascal Godet

  • Katharina Kusejko

  • Marcel Stoeckle

  • Matthias Cavassini

  • Huldrych F Günthard

  • Enos Bernasconi

  • Alexandra Calmy

  • Patrick Schmid

  • Cornelia Staehelin

  • Niklaus D Labhardt

  • Heiner C Bucher

  • Swiss HIV Cohort Study

  • I Abela

  • K Aebi-Popp

  • A Anagnostopoulos

  • M Battegay

  • E Bernasconi

  • D L Braun

  • H C Bucher

  • A Calmy

  • M Cavassini

  • A Ciuffi

  • G Dollenmaier

  • M Egger

  • L Elzi

  • J Fehr

  • J Fellay

  • H Furrer

  • C A Fux

  • H F Günthard

  • A Hachfeld

  • D Haerry

  • B Hasse

  • H H Hirsch

  • M Hoffmann

  • I Hösli

  • M Huber

  • C R Kahlert

  • L Kaiser

  • O Keiser

  • T Klimkait

  • R D Kouyos

  • H Kovari

  • K Kusejko

  • G Martinetti

  • B Martinez de Tejada

  • C Marzolini

  • K J Metzner

  • N Müller

  • J Nemeth

  • D Nicca

  • P Paioni

  • G Pantaleo

  • M Perreau

  • A Rauch

  • P Schmid

  • R Speck

  • M Stöckle

  • P Tarr

  • A Trkola

  • G Wandeler

  • S Yerly

  • July 16, 2025

  • 0 min

Share

  • 1

    The study linked Swiss HIV Cohort data with health insurer claims to analyze healthcare costs for HIV and HCV treatment from 2012 to 2017.

  • 2

    Mean annual healthcare costs for HIV management increased slightly from CHF 24,713 in 2012 to CHF 24,881 in 2017, with ART costs decreasing over time.

  • 3

    Hospitalization costs rose significantly, averaging CHF 9,406 in 2017, reflecting a 7.2% annual increase from CHF 8,727 in 2012.

  • 4

    Direct-acting agents (DAAs) for HCV treatment contributed marginally to overall costs, averaging CHF 52,647 for 171 patients coinfected with HCV.

  • 5

    The study highlights the challenges in analyzing healthcare costs due to the lack of unique patient identifiers and diagnostic codes in Swiss claims data.

Original Source(s)

Trends in Costs for HIV Care During a Hepatitis C Virus Early Treatment and Elimination Program: A Data Linkage Study of Claims and Swiss HIV Cohort Study Data

  • by Soheila Aghlmandi, Kurt Schmidlin, Carola Huber, Pascal Godet, Katharina Kusejko, Marcel Stoeckle, Matthias Cavassini, Huldrych F Günthard, Enos Bernasconi, Alexandra Calmy, Patrick Schmid, Cornelia Staehelin, Niklaus D Labhardt, Heiner C Bucher, Swiss HIV Cohort Study, I Abela, K Aebi-Popp, A Anagnostopoulos, M Battegay, E Bernasconi, D L Braun, H C Bucher, A Calmy, M Cavassini, A Ciuffi, G Dollenmaier, M Egger, L Elzi, J Fehr, J Fellay, H Furrer, C A Fux, H F Günthard, A Hachfeld, D Haerry, B Hasse, H H Hirsch, M Hoffmann, I Hösli, M Huber, C R Kahlert, L Kaiser, O Keiser, T Klimkait, R D Kouyos, H Kovari, K Kusejko, G Martinetti, B Martinez de Tejada, C Marzolini, K J Metzner, N Müller, J Nemeth, D Nicca, P Paioni, G Pantaleo, M Perreau, A Rauch, P Schmid, R Speck, M Stöckle, P Tarr, A Trkola, G Wandeler, S Yerly

  • July 16, 2025

Related Content

Impact of Viral Infections on Immune Microenvironment Alterations and Responses to Immune Checkpoint Therapy: Interactions Between Infection, Immunity, and Cancer

Accessing Syringe Services Programs in the US: Analyzing Travel Time, Distance, and Associated Costs

The Journey to Hepatitis C Elimination in Taiwan: Insights From the Hemodialysis Population